PetMed Express (PETS)
(Delayed Data from NSDQ)
$4.70 USD
-0.37 (-7.30%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $4.80 +0.10 (2.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.70 USD
-0.37 (-7.30%)
Updated Nov 15, 2024 04:00 PM ET
After-Market: $4.80 +0.10 (2.13%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Zacks News
QIAGEN (QGEN) Meets Q3 Earnings, Lags Revenues, Keeps View
by Zacks Equity Research
QIAGEN's (QGEN) top line gains from strength in the Molecular Diagnostics space in Q3.
Zacks.com featured highlights: PetMed Express, Microsoft, Rockwell Collins, Jones Lang LaSalle and Owens Corning
by Zacks Equity Research
Zacks.com featured highlights: PetMed Express, Microsoft, Rockwell Collins, Jones Lang LaSalle and Owens Corning
Hill-Rom (HRC) Q4 Earnings and Revenues Top, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) witnesses strong revenue growth in Q4, driven by a solid momentum in core business, acquisition of Mortara and contribution from product launches.
CVS Health (CVS) Beats Q3 Earnings Estimates, Updates View
by Zacks Equity Research
CVS Health (CVS) witnesses year-over-year growth in revenues on the back of strength in the Pharmacy Services segment in Q3.
Henry Schein (HSIC) Misses Q3 Earnings, Margins Decline
by Zacks Equity Research
Henry Schein (HSIC) maintains stellar top-line performance in Q3, courtesy of strength in all business segments.
Fresenius Medical (FMS) Q3 Earnings Miss, FY17 View Intact
by Zacks Equity Research
Strong growth in Health Care Products and Health Care Services segments drove Fresenius's (FMS) third-quarter revenues. Lackluster performance by the renal pharmaceutical segment is a concern.
CONMED (CNMD) Q3 Earnings and Revenues Beat, Margin Down
by Zacks Equity Research
CONMED (CNMD) gains from strength in General Surgery business in Q3, driven by strong performances by Advanced Surgical and Endoscopic Technologies.
Cardinal Health (CAH) Beats on Q1 Earnings, FY18 View Intact
by Zacks Equity Research
Solid growth at Medical Segment drove Cardinal Health's (CAH) first-quarter results. Product launches and completion of strategic acquisitions in the quarter are major positives.
6 Solid Dividend Growth Stocks for Higher Returns
by Sweta Killa
Given that the stock market is at its peak, investors are looking for both income and growth in their portfolios.
BioScrip (BIOS) Q3 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
BioSrip (BIOS) Q3 revenues affected by the company's shift in strategy to focus on core revenue mix, the impact of the Cures Act and contract modifications with UnitedHealthcare.
Bruker (BRKR) Q3 Earnings & Revenues Beat Estimates, View Up
by Zacks Equity Research
Bruker (BRKR) raises 2017 guidance. The year-over-year increase in Q3 revenues encourages.
Allscripts (MDRX) Q3 Earnings Meet, Revenues Beat Estimates
by Zacks Equity Research
Allscripts' (MDRX) solid guidance for 2017 and a bullish long-term outlook are key highlights of Q3. The expansion in margins is encouraging.
PerkinElmer (PKI) Beats Q3 Earnings, Updates '17 Guidance
by Zacks Equity Research
PerkinElmer (PKI) posted stellar third-quarter numbers from strong performance in particularly the Diagnostics segment.
Pacific Biosciences (PACB) Q3 Loss Narrower Than Estimated
by Zacks Equity Research
Pacific Biosciences (PACB) witnesses solid contribution from the Instrument and Consumable revenue platforms. Consumable revenue growth was driven by higher installed base of instruments.
DENTSPLY (XRAY) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) reported third-quarter 2017 adjusted earnings per share (EPS) of 70 cents, beating the Zacks Consensus Estimate by 4 cents.
Align Technology (ALGN) Gains on InvisAlign, Competition Rife
by Zacks Equity Research
Align Technology (ALGN) continues to gain from strength in the InvisAlign space.
DexCom (DXCM) Q3 Loss Narrower Than Expected, Revenues Meet
by Zacks Equity Research
DexCom (DXCM) rides high on Sensor and Transmitter revenues in Q3.
Omnicell's Higher Investments Drive Costs, Competition Rife
by Zacks Equity Research
Omnicell (OMCL) continues to battle escalating costs emanating from several strategies adopted by the company. A tough competitive landscape also acts as a dampener.
AmerisourceBergen (ABC) Beats Q4 Earnings, Issues FY18 View
by Zacks Equity Research
Solid growth in the Pharmaceutical Distribution Services segment drove AmerisourceBergen's (ABC) top line in the fourth quarter.
STERIS (STE) Q2 Earnings Miss & Revenues Beat, Margins Up
by Zacks Equity Research
STERIS (STE) witnessed year-over-year decline in Q2 revenues due to softness in Healthcare Products and the Healthcare Specialty Services segments.
Integra Gains on Global Growth, Hurricanes Hamper Business
by Zacks Equity Research
Integra (IART) launches new regenerative products within its Orthopedics and Tissue Technologies segment. However, hurricanes in Q3 grossly affect the wound care and orthopedic procedures in Florida.
Becton, Dickinson (BDX) Beats on Q4 Earnings, Guidance Solid
by Zacks Equity Research
Becton, Dickinson's (BDX) guidance for fiscal 2018 buoys optimism for investors. The company's Life Sciences business will be a key growth driver.
Zacks Market Edge Highlights: SPDR S&P 600 Small Cap, First Trust NASDAQ Community Bank, Ultra Clean, PetMed Express and MKS Instruments
by Zacks Equity Research
Zacks Market Edge Highlights: SPDR S&P 600 Small Cap, First Trust NASDAQ Community Bank, Ultra Clean, PetMed Express and MKS Instruments
Wright Medical Group (WMGI) Q3 Earnings In Line, Sales Miss
by Zacks Equity Research
Wright Medical (WMGI) posted loss as estimated in the third quarter on lower-than-expected sales.
Zimmer Biomet's (ZBH) Q3 Earnings Lag Estimates, View Down
by Zacks Equity Research
Zimmer Biomet's (ZBH) declining revenue performance within most of the core segments, along with a rise in cost of products sold resulted in bottom line pressure in the third quarter.